通用感染疾病市场规模、份额及成长分析（依疾病类型、治疗类型、给药途径、最终使用者和地区）－2025-2032 年产业预测

通用感染疾病市场规模预计在 2023 年达到 416.5 亿美元，并从 2024 年的 442.3 亿美元增长到 2032 年的 715.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.2%。

据美国疾病管制与预防中心称，通用感染疾病（由动物传播给人类）预计每年将影响数以万计的美国人。快速的都市化和人口成长可能会加剧这些问题，特别是在卫生条件较差的地区。此外，对动物性蛋白质和脂肪的需求不断增加预计将推动通用感染疾病治疗市场的发展。宠物的广泛拥有在提供陪伴的同时也带来了疾病传播的风险。然而，新兴国家认知度低、研究成本高等障碍可能会阻碍市场成长。然而，由于针对动物健康需求的创新治疗方法的发展，预计未来几年全球市场将会扩大。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

通用感染疾病市场规模（依疾病类型及复合年增长率） (2025-2032)

• 市场概览
• 狂犬病
• 莱姆病
• 兹卡病毒
• 西尼罗病毒
• 汉他病毒
• 疟疾
• 结核
• 回归热
• 病毒性肝炎
• 其他的

通用感染疾病市场规模（依治疗类型及复合年增长率） (2025-2032)

• 市场概览
• 疫苗
• 抗病毒药物
• 抗生素
• 免疫球蛋白
• 抗生素
• 抗真菌药物
• 其他的

通用感染疾病市场规模（依给药途径及复合年增长率） (2025-2032)

• 市场概览
• 静脉
• 肌肉注射
• 口服

通用感染疾病市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 门诊手术中心
• 家庭护理设置
• 研究组织
• 诊所

通用感染疾病市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• GlaxoSmithKline plc（UK）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• AstraZeneca plc（UK）
• Bayer AG（Germany）
• Eli Lilly and Company（USA）
• AbbVie Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Bristol-Myers Squibb Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim GmbH（Germany）
• BioNTech SE（Germany）
• Moderna, Inc.（USA）
• Inovio Pharmaceuticals, Inc.（USA）
• Emergent BioSolutions Inc.（USA）

结论和建议

Zoonotic Disease Treatment Market size was valued at USD 41.65 billion in 2023 and is poised to grow from USD 44.23 billion in 2024 to USD 71.57 billion by 2032, growing at a CAGR of 6.2% during the forecast period (2025-2032).

According to the Centers for Disease Control and Prevention, zoonotic diseases, transmitted from animals to humans, are projected to afflict tens of thousands of Americans annually. Rapid urbanization and population growth are likely to exacerbate these issues, especially in areas with poor sanitation. Additionally, the increasing demand for animal proteins and fats is expected to drive the market for zoonotic disease treatments. The prevalence of pet ownership provides companionship but also introduces the risk of disease transmission. However, barriers such as limited awareness in developing countries and high research costs could hinder market growth. Nonetheless, the global market is poised for expansion with the development of innovative therapies tailored to animal health needs in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Zoonotic Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Zoonotic Disease Treatment Market Segments Analysis

Global Zoonotic Disease Treatment Market is segmented by Disease Type, Treatment Type, Administration Route, End User and region. Based on Disease Type, the market is segmented into Rabies, Lyme Disease, Zika Virus, West Nile Virus, Hantavirus, Malaria, Tuberculosis, Relapsing Fever, Viral Hepatitis and Others. Based on Treatment Type, the market is segmented into Vaccines, Antiviral Drugs, Antibiotics, Immunoglobulins, Antibacterial Medication, Antifungal Medication and Others. Based on Administration Route, the market is segmented into Intravenous, Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Homecare Settings, Research Institutions and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is being propelled by a multitude of factors, including the surging occurrence of zoonotic diseases and a growing awareness of their transmission. Additionally, the continuous development of innovative and effective treatments, alongside supportive government initiatives, plays a significant role in market growth. Furthermore, technological advancements and a rise in investments directed toward research and development further contribute to the expansion of this market. Collectively, these elements underscore the urgent need for effective treatment options and underscore the importance of addressing zoonotic diseases in public health strategies.

Restraints in the Zoonotic Disease Treatment Market

Despite the considerable growth potential of the zoonotic disease treatment market, several factors may impede its progress. The limited availability of effective treatments and the high costs associated with these therapies are significant barriers. Additionally, insufficient investment in research and development presents a further challenge. The market's growth may also be affected by the rise of generic medications and the impending patent expirations of established brands. Furthermore, a shortage of skilled professionals and inadequate healthcare infrastructure in developing countries complicate the situation. High capital requirements for research and development, coupled with a general lack of public awareness, further restrain market expansion.

Market Trends of the Zoonotic Disease Treatment Market

The Zoonotic Disease Treatment market is experiencing a significant upward trend, propelled by the rising incidence of zoonotic infections linked to urbanization, deforestation, and climate change. As ecosystems are disrupted, the interaction between humans and wildlife intensifies, facilitating the transmission of pathogens. This surge in disease awareness is prompting an urgent demand for innovative treatments and vaccines. Furthermore, increased government funding for research and development, alongside advancements in biotechnology, are catalyzing market expansion. With a growing focus on preventative measures and rapid response strategies, the Zoonotic Disease Treatment market is poised for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Zoonotic Disease Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Rabies
• Lyme Disease
• Zika Virus
• West Nile Virus
• Hantavirus
• Malaria
• Tuberculosis
• Relapsing Fever
• Viral Hepatitis
• Others

Global Zoonotic Disease Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Vaccines
• Antiviral Drugs
• Antibiotics
• Immunoglobulins
• Antibacterial Medication
• Antifungal Medication
• Others

Global Zoonotic Disease Treatment Market Size by Administration Route & CAGR (2025-2032)

• Market Overview
• Intravenous
• Intramuscular
• Oral

Global Zoonotic Disease Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Homecare Settings
• Research Institutions
• Clinics

Global Zoonotic Disease Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Treatment Type, Administration Route, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Administration Route, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Administration Route, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Administration Route, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Administration Route, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations